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Abstract
To assess psychosocial and somatic risk factors related to pregnancy, and pregnancy-related complications or disorders in women
with schizophrenia compared to population controls. In this register-based cohort study, we identified all Finnish women who
were born in 1965–1980 and diagnosed with schizophrenia in psychiatric care before 31 December 2013. For each case, five age-
and place-of-birth matched controls were randomly selected. They were followed from the day when the disorder was diagnosed
in specialized health care till the end of 2013. The mean follow-up time was 14.0 + 6.91 vs. 14.3 + 6.89 years. Altogether, 1162
singleton pregnancies were found among affected women and 4683 among controls. Affected women were significantly older
and more often single; their body mass index before pregnancy was significantly higher, and they smoked significantly more
often both in the beginning of pregnancy and after the first trimester than controls. They showed a significantly higher odds for
pathologic oral glucose tolerance test (odds ratio (OR) 1.66, 95% confidence interval (95% CI) 1.27–2.17), initiation of insulin
treatment (OR 1.84, 95% CI 1.15–2.93), fast fetal growth (OR 1.62, 95% CI 1.03–2.52), premature contractions (OR 2.42, 95%
CI 1.31–4.49), hypertension (OR 1.81, 95% CI 1.01–3.27), and pregnancy-related hospitalizations (OR 1.97, 95% CI 1.66–
2.33). Suspected damage to the fetus from alcohol/drugs was significantly more common among affected women than controls.
Women with schizophrenia have higher prevalence of psychosocial and somatic risk factors related to pregnancy, as well as
pregnancy-related complications and disorders than non-affected women.
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Introduction
There has been an increase in pregnancies among women with
schizophrenia spectrum disorders (Matevosyan 2011; Solari
et al. 2009). For example, in Ontario, Canada, the general
fertility rate among women with schizophrenia was 16%
higher in 2007–2009 than in 1996–1998 (the incidence rate
ratio (IRR) 1.16, 95% confidence interval (CI) 1.04–1.31)
(Vigod et al. 2012). However, research focusing on their re-
productive health is still scarce and often limited by modest
sample sizes. Overall, women with schizophrenia less often
have a partner or spouse (Matevosyan 2011) and their preg-
nancies are more often unplanned than those of healthy wom-
en (Matevosyan 2011). Regarding health conditions which
increase the risk for problems during pregnancy, women with
schizophrenia have a higher risk of obesity and metabolic
syndrome (Dipasquale et al. 2013) than the general popula-
tion. The prevalence of smoking is high in people with schizo-
phrenia (Dalack et al. 1998) and, according to a meta-analysis
by Koskinen et al. (2009), approximately, 20% of them have a
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lifetime diagnosis of alcohol use disorder. Pregnant women
with schizophrenia may be more likely to smoke
(Bennedsen 1998; Judd et al. 2014) and use alcohol
(Bennedsen 1998) and illicit drugs (Judd et al. 2014) than
other pregnant women. Pregnancy also appears to worsen
the mental health of some women with schizophrenia. As
compared to other pregnant women, those with a history of
psychosis have reported more anxiety, socio-economical and
interpersonal problems, fear about delivery, as well as lack of
confidence about their ability to parent (McNeil et al. 1983).
Regarding adverse pregnancy outcomes, women with schizo-
phrenia are found to be at higher risk of venous thromboem-
bolism (Ellman et al. 2007), pre-eclampsia/eclampsia (Ellman
et al. 2007; Judd et al. 2014; Nguyen et al. 2013; Vigod et al.
2014), and gestational diabetes (Judd et al. 2014; Nguyen
et al. 2013) and they have shown a tendency for higher ges-
tational hypertension (Ellman et al. 2007) and increased rates
of prenatal hospitalizations (Ellman et al. 2007; Vigod et al.
2014). In contrast, women with schizophrenia have reported
receiving less prenatal care than their healthy counterparts
(Miller and Finnerty 1996).
Pregnancy and maternity care are influenced by both cul-
tural and socio-economic conditions, as well as the provision
and funding of healthcare services. Therefore, research find-
ings may be context-specific and the generalizability of find-
ings between settings, countries, and time periods is uncertain.
The purpose of this Finnish register-based national population
study was to investigate pregnancy-related health outcomes
and complications in women with schizophrenia or
schizoaffective disorder. We hypothesized that compared to
non-affected women, women with schizophrenia would show
higher prevalence of psychosocial and somatic risk factors
related to pregnancy, as well as pregnancy-related complica-
tions and disorders. Finally, we predicted that, as a conse-
quence of this, women with schizophrenia would have re-
ceived more intense prenatal care compared to their non-
affected counterparts.
Materials and methods
Participants
The sample comprised a Finnish national population of wom-
en who were born between Jan. 1, 1965 and Dec. 31, 1980,
and diagnosed with schizophrenia or schizoaffective disorder
(here, schizophrenia) in specialized health care at some point
during the follow-up time ending Dec. 31, 2013 (N = 5214).
For each woman with schizophrenia, five age- and place-of-
birth matched controls were randomly selected from the
Finnish Central Population Register (N = 25,999). They had
not been diagnosed with schizophrenia, schizoaffective disor-
der or any other psychotic disorder by the end of the follow-up
time, but other mental health disorders were allowed. For fur-
ther information, see Simoila et al. (2018). Flow chart of the
sampling of participants is presented in Fig. 1 .
Diagnoses
We used the Care Register for Health Care of the National
Institute of Health and Welfare to obtain the psychiatric diag-
noses. In Finland, the International Classification of
Diseases—Eighth Revision (ICD-8) (World Health
Organization 1965) was used between 1969 and 1986 (schizo-
phrenia 295.0–6, 295.8–9; schizoaffective psychosis 295.7).
The third revision of the Diagnostic and Statistical Manual of
Mental Disorders (DSM-III-R) (American Psychiatric
Association 1987) was used between 1987 and 1995, but the
diagnoses were converted to the International Classification of
Disease—Ninth Revision (ICD-9) (World Health
Organization 1977) codes (schizophrenia: 295.0–6, 295.8–9;
schizoaffective psychosis: 295.7). The International
Classification of Diseases—Tenth Revision (ICD-10) (World
Health organization 1992) has been used since 1996 (schizo-
phrenia, F20; schizoaffective psychosis, F25). The onset of
schizophrenia was defined as the day the disorder was diag-
nosed and coded in specialized health care.
Follow-up
Women were followed from the onset of the disorder until the
individual moved abroad, died, or follow-up ended on
Dec. 31, 2013. Death or emigration information was gathered
from the Finnish Central Population Register. The mean
follow-up time of women with schizophrenia was 14.0 (SD
6.91) years, and, respectively, of controls 14.3 (SD 6.89) years
(p = 0.001).
All Finnish women who were born between 
1965 and 1980 and diagnosed with 
schizophrenia or schizoaffective disorder till 
31.12.2013
n = 5214
Women who gave birth after being 
diagnosed with the disorder and after the 
Medical Birth Register was introduced in 
1987, the follow up ended 31.12.2013
n = 761
Randomly selected age- and place-of-
birth -matched control women (1:5)
n = 25 999
Controls who gave birth after the 
index day (= the day when the case 
was diagnosed with schizophrenia or 
schizoaffective disorder)
n = 2472
First singleton birth after the diagnosis
n = 753
All singleton births after the diagnosis
n = 1162
First singleton birth after the index day
n = 2434
All singleton births after the index day
n = 4683
Fig. 1 Flow chart of the study project
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Information on pregnancy
Data were obtained from the Medical Birth Register, main-
tained by the National Institute of Health and Welfare since
1987. This register covers all delivery hospitals in Finland and
includes data on live births and stillbirths of fetuses with a
birth weight of at least 500 g or a gestational age of at least
22 weeks, as well as data on the mothers. Healthcare profes-
sionals (midwife, nurse, etc.) fill in a data collection form or
record the same information electronically. The National
Institute of Health and Welfare has the responsibility to
check the data quality. It has been reported that most of the
register content corresponds well or satisfactorily with
medical records. More precisely, in 1991, Gissler et al.
(1995) studied the agreement percentage (%) of the Medical
Birth Register andmedical records and reported the following:
mother’s identification number 99.0%, marital status 95.0%,
smoking status 93.4%, previous pregnancies 96.3%, previous
deliveries 97.4%, gestational age 86.2%, first antenatal visit
94.7%, birth weight 99.0%, 1-min Apgar score 99.5%, and the
number of antenatal care visits 62.4%. In this study, all preg-
nancies leading to singleton births during the follow-up period
were included whereas multiple pregnancies were excluded.
We used the following data from the Medical Birth
Register: gestational age, parity, maternal age at birth, marital
status at the end of the pregnancy, smoking status in the be-
ginning of the pregnancy and after the first trimester (recorded
since 1991), weight and height before the pregnancy in order
to calculate body mass index, BMI = kg/m2 (recorded since
2004), as well as the following pregnancy complications (re-
corded since 2004): pathological oral glucose tolerance test,
initiation of insulin treatment, anemia, and antenatal cortico-
steroid treatment. The following ICD-10 (World Health
organization 1992) diagnoses used for conditions related to
or aggravated by the pregnancy (here, pregnancy-related dis-
orders) (recorded since 2004) were collected: hypertension
(O13, O16), slow fetal growth (O36.5, P05.0, P05.1, P05.9),
fast fetal growth (O36.6), pre-eclampsia (O14), hepatogestosis
(O26.6), any vein complication (O22), premature rupture of
membrane (O42), oligohydramnios (O41.0), hyperemesis
gravidarum (O21.0, O21.1, O21.2, O21.9), urogenital infec-
tion (O23), symphyseolysis (O26.7), premature contractions
(O47), suspected fetal hypoxia (O36.3), fear of childbirth
(O99.80), and suspected fetal injury due to alcohol/drugs
(O35.4, O35.5). The data also included variables related to
prenatal care: the number of visits to the municipal maternity
clinic, the number of outpatient visits to maternity hospital,
and hospitalizations related to pregnancy complications or
disorders. In Finland, every municipality has its own materni-
ty clinics, which serve mothers-to-be free of charge. Women
are advised to contact their local maternity clinic as soon as
they find out they are pregnant. The first visit is usually at the
gestational age of 8 to 10 weeks. Mothers-to-be with
substantial healthcare problems are referred to secondary
health care units (outpatient clinics and wards of maternity
hospitals).
Ethics
The Ethics Committee of the Helsinki and Uusimaa Hospital
District evaluated the study plan, and the Helsinki University
Hospital, and the National Institute of Health and Welfare
granted the permission to conduct the study project.
Data analysis
The analyses were performed in two ways: first, we included
each woman’s first singleton pregnancy, which lead to a de-
livery after she was diagnosed with schizophrenia. Second, we
included eachwoman’s all singleton pregnancies, which led to
deliveries after she was diagnosed with schizophrenia. We
compared the groups using the chi-square (χ2) test (cohabit-
ing/married at the end of pregnancy, smoking in the beginning
of pregnancy, smoking after the first trimester of pregnancy,
pregnancy-related complications and disorders, individuals
with one or more hospitalizations), Fisher’s exact test (some
pregnancy-related disorders), and independent samples t test
(age, BMI, parity, number of visits to municipal maternity
clinic, number of outpatient visits to maternity hospital).
Findings were considered significant when the two-tailed p
value < 0.05. Coefficient Phi (x2 test) and Cohen’s dwere used
as measures of effect size. The magnitude of Phi was
interpreted as follows: 0.1 as small, 0.3 as moderate, and 0.5
as large effect, and respectively, Cohen’s d as follows: 0.2 as
small, 0.5 as moderate, and 0.8 as large effect (Cohen 1992).
Next, logistic regression analysis was performed to analyze
associations between schizophrenia and pregnancy-related
complications and disorders, as well as hospitalizations related
to pregnancy during the first pregnancy. With regard to all
pregnancies, in order to take into account the clustering of
pregnancies within mothers, logistic regression analysis was
performed using the generalized estimating equation (GEE)
method. Analyses were done unadjusted, but also adjusted
models were constructed in order to control for potential con-
founding factors. Maternal age at birth, marital status (single
vs. married/cohabitation), smoking status in the beginning of
the pregnancy (yes/no), and parity were chosen to serve as
covariates, since all these four variables might independently
explain group differences in outcomes, and all had shown
good validity in a previous data quality study by Gissler
et al. (1995). Variables with less than 10 affected women (in
the schizophrenia group, or in the control group, or in both
groups) were omitted since such models were considered un-
stable. Odds ratios (ORs) with 95% CI are reported. Findings
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were considered significant when the p value for the regres-
sion model was < 0.05.
Analyses were performed using SPSS 22.0 for Windows
and SAS 9.3.
Results
After the index day, 761 women with schizophrenia and 2472
controls gave birth at least once. Parity measured as the mean
number of deliveries was 1.54 (SD 0.92) among women with
schizophrenia and 1.92 (SD 0.99) among non-affected women
(t = − 4.260, p < 0.001).
There were altogether 1184 births among women with
schizophrenia. We focused on singleton births and identified
altogether 1162 (98.1%) singleton births, of which 753
(64.8%) were the first births after the diagnosis. Altogether
205 women had given birth already before they were diag-
nosed with schizophrenia, but these births (n = 359) were not
included into the analyses. We restricted the analysis of births
in controls to those that occurred after the index day of the
case, which led to 4848 births, of which 4683 (96.7%) were
singleton births. Of these singleton births, 2434 (52.0%) were
the first births after the index day.
Gestational age of the fetus and woman’s first visit
in maternity clinic
Regarding first pregnancies, the mean gestational age of the
fetus was 10.4 weeks (SD 4.94) among women with schizo-
phrenia and 9.3 weeks (SD 2.71) among controls (t = 5.844,
p < 0.001). Regarding all pregnancies, the mean gestational
age was 10.2 weeks (SD 4.60) among women with schizo-
phrenia and 9.4 (SD 2.73) among controls (t = 5.670,
p < 0.001).
Delay between the diagnosis and the first visit
in maternity clinic
Among women with schizophrenia, the mean delay between
the diagnosis and the first visit in maternity clinic was 5.5 (SD
4.20) years when first pregnancies were taken into consider-
ation. Regarding all pregnancies, this delay was 6.8 (SD 4.56)
years. The sample included 64 women who were diagnosed
with schizophrenia during the pregnancy.
Psychosocial and somatic risk factors related
to pregnancy
Regarding first pregnancies, women with schizophrenia were
significantly older during their first pregnancy (Table 1).
When all pregnancies were taken into consideration, no statis-
tically significant difference in age was noticed. Regarding
both first pregnancies and all pregnancies, women with
schizophrenia were more often single at the end of pregnancy
compared to their controls. Further, they exhibited significant-
ly higher BMI before pregnancy and smoked significantly
more often, both in the beginning of pregnancy and after the
first trimester.
Pregnancy-related complications and disorders
Regarding both first pregnancies and all pregnancies, women
with schizophrenia exhibited significantly more often than
controls pathologic glucose tolerance test, initiation of insulin
treatment and anemia (Table 2). Further, suspected fetal injury
due to alcohol/drugs was significantly more prevalent among
women with schizophrenia than among controls. Regarding
first pregnancies, women with schizophrenia suffered signifi-
cantly more often than controls from premature contractions
and fast fetal growth. However, when all pregnancies were
taken into consideration, differences in these variables were
not statistically significant. With regard to all pregnancies,
exhaustion was significantly more prevalent among women
with schizophrenia than among controls. However, when only
first pregnancies were taken into consideration, no statistically
significant difference in exhaustion was observed.
Prenatal care
Regarding both first pregnancies and all pregnancies, the
number of municipal maternity clinic visits as well as the
number of visits to maternity hospital policlinics was signifi-
cantly higher among women with schizophrenia than among
controls (Table 3). Also, the proportion of women with one or
more pregnancy-related hospitalizations was significantly
higher among women with schizophrenia than among
controls.
Associations between schizophrenia
and pregnancy-related complications/disorders
and hospitalizations
Regarding first pregnancies, in unadjusted model, women
with schizophrenia exhibited a 2-fold increased risk of patho-
logical oral glucose tolerance test, an over 2-fold increased
risk of anemia, and an almost 2-fold increased risk of being
hospitalized at least once because of pregnancy-related com-
plications or disorders (Table 4). In adjusted model, women
with schizophrenia showed an almost 2-fold increased risk of
pathological oral glucose tolerance test and hypertension and
an over 2-fold increased risk of premature contractions. Their
risk of hospitalization was over 2-fold higher. Regarding all
pregnancies, in unadjusted model, women with schizophrenia
exhibited an almost 2-fold risk of pathologic oral glucose tol-
erance test and anemia. Their risk of hospitalization was
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almost 2-fold. In adjusted model, women with schizophrenia
showed an almost 2-fold increased risk of pathologic oral
glucose tolerance test, initiation of insulin treatment, and fast
fetal growth. Their risk of hospitalization was almost 2-fold
higher.
Discussion
This register-based national population study comprised all
pregnancies of women born in 1965–1980 who were diag-
nosed with schizophrenia in Finland. As we hypothesized,
women with schizophrenia showed a higher prevalence of
pregnancy-related psychosocial and somatic risk factors, as
well as pregnancy-related complications and disorders than
their non-affected counterparts. They had also received more
intense prenatal care than their controls. Overall, findings re-
lated to first pregnancies and those related to all pregnancies
were much alike. Thus, it seems that risk factors and problems
related to pregnancy persist irrespective of parity among
women with schizophrenia.
Regarding risk factors, women with schizophrenia showed
significantly higher BMI before pregnancy. The finding was
expected, since among patients with schizophrenia, obesity is
approximately twice as prevalent as in the general population
(Allison et al. 2009). This is mostly due to antipsychotic med-
ications, unhealthy diet, and sedentary lifestyle (Manu et al.
2015). Negative symptoms of schizophrenia including apathy,
lack of drive and volition, and withdrawal from social inter-
action can hamper a patient’s ability to take care of herself, as
well as to reduce her motivation to participate activities.
Lifestyle interventions that target diet, exercise, and behavior
are important for prevention and treatment of being over-
weight or obese (Ward et al. 2015). This is also true for indi-
viduals with severe mental illness: a recent meta-analysis of
25 lifestyle interventions showed large effect sizes in weight
gain prevention and moderate effect sizes in weight loss stud-
ies (Bruins et al. 2014). We found that women with schizo-
phrenia smoked significantly more often in the beginning of
pregnancy, as well as after the first trimester than the unex-
posed women. Poverty and low education level (Tidey and
Miller 2015), the self-medication hypothesis (Rüther et al.
2014), and common genetic pathways (Loukola et al. 2014)
may explain the strong relationship between nicotine depen-
dency and schizophrenia. However, individuals with schizo-
phrenia are interested in and capable of smoking cessation
(Dickerson et al. 2013; Gilbody et al. 2015). In summary,
our findings underline the need for targeted health education
and lifestyle interventions for women with schizophrenia who
plan pregnancy or have become pregnant, and possibly also
for those at risk for unplanned pregnancy.
As in recent studies (Judd et al. 2014; Nguyen et al. 2013),
affected women with their first pregnancies showed a 1.5-fold
increased risk of pathologic oral glucose tolerance test. In all
pregnancies, with adjustment for the clustering of pregnancies
within mothers, women with schizophrenia showed almost a
Table 1 Psychosocial and
somatic risk factors related to
pregnancy in women with
schizophrenia (SZH) and their
controls
First pregnancies* SZH (n = 753) Controls (n = 2434) p value ES
Age at birtha; mean + SD 30.1 + 5.2 29.2 + 4.3 < 0.001 0.20
Cohabiting/married at the end
of pregnancya; n (%)
540 (71.7) 2138 (87.8) < 0.001 0.18*
Smoking in the beginning of pregnancya; n (%) 274 (36.4) 339 (13.9) < 0.001 0.24*
Smoking after the first trimester
of pregnancyb; n (%)
243 (33.0) 260 (10.9) < 0.001 0.25*
BMI before pregnancyc; mean + SD 25.8 + 5.2 24.5 + 4.6 < 0.001 0.27
All pregnancies* SZH (n = 1162) Controls (n = 4683) p value
Age at birtha; mean + SD 30.7 + 4.9 30.4 + 4.5 0.104 0.06
Cohabiting/married at the end
of pregnancya; n (%)
895 (77.0) 4252 (90.8) < 0.001 0.17*
Smoking in the beginning of pregnancya; n (%) 408 (35.1) 568 (12.1) < 0.001 0.25*
Smoking after the first trimester
of pregnancyb; n (%)
360 (31.6) 450 (9.8) < 0.001 0.25*
BMI before pregnancyc; mean + SD 26.4 + 5.7 24.8 + 4.8 < 0.001 0.30
SD standard deviation, ES effect size, BMI body mass index
*Leading to a delivery after the person was diagnosed with schizophrenia. The chi-square (χ2 ) test and indepen-
dent samples t test (age, BMI, parity) were used to compare the groups. Coefficient Phi (x2 test)* and Cohen’s d
(independent samples t test) were used as effect size measures
a Recorded since 1987
b Recorded since 1991
c Recorded since 2004
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2-fold increased risk of both pathological oral glucose toler-
ance test and initiation of insulin treatment. Furthermore, in
accordance with Vigod et al. (2014), their risk of fast fetal
growth was approximately 1.6-fold higher. This is probably
explained by maternal hyperglycemia, since offsprings of
mothers with gestational diabetes have higher weights at birth
and later in life (Baptiste-Roberts et al. 2012). A recent meta-
analysis on nutrition interventions among individuals with a
Table 2 Conditions related to or
aggravated by the pregnancya in
women with schizophrenia (SZH)
and their controls
First pregnancies*; n (%) SZH (n = 753) Controls (n = 2434) p value ES
Pathologic oral glucose tolerance test 75 (10.2) 115 (4.8) < 0.001 0.28
Initiation of insulin treatment 17 (2.3) 27 (1.1) 0.018 0.18
Anemia 12 (1.6) 15 (0.6) 0.001 0.27
Antenatal corticosteroid treatment 8 (1.1) 19 (0.8) 0.461 < 0.10
Premature contractions 17 (2.0) 30 (1.3) 0.041 0.11
Hypertension 15 (2.0) 33 (1.4) 0.210 < 0.10
Suspected fetal injury due to alcohol/drugs 9 (2.4) 1 (0.04) < 0.001 NA
Fast fetal growth 8 (1.1) 8 (0.3) 0.013 < 0.10
Slow fetal growth 7 (0.9) 12 (0.5) 0.174 < 0.10
Fear of childbirth 6 (0.8) 12 (0.5) 0.331 NA
Pre-eclampsia 6 (0.8) 26 (1.1) 0.514 NA
Premature rupture of membrane 4 (0.5) 21 (0.9) 0.482 NA
Hepatogestosis 3 (0.4) 8 (0.3) 0.728 NA
Oligohydramnios 2 (0.1) 12 (0.5) 0.541 NA
Any vein complication 2 (0.1) 1 (0.04) 0.141 NA
Exhaustion 2 (0.2) 2 (0.1) 0.239 NA
Hyperemesis gravidarum 1 (0.1) 2 (0.1) 0.555 NA
Urogenital infection 1 (0.1) 2 (0.1) 0.555 NA
Symphyseolysis 1 (0.1) 1 (0.04) 0.417 NA
All pregnancies*; n (%) SZH (n = 1162) Controls (n = 4683) p value ES
Pathologic oral glucose tolerance test 132 (11.6) 290 (6.3) < 0.001 0.29
Initiation of insulin treatment 35 (3.1) 69 (1.5) < 0.001 0.19
Anemia 22 (1.9) 44 (1.0) 0.006 0.12
Antenatal corticosteroid treatment 11 (1.0) 34 (0.7) 0.441 < 0.10
Premature contractions 24 (2.1) 78 (1.7) 0.351 < 0.10
Hypertension 18 (1.6) 57 (1.2) 0.368 < 0.10
Suspected fetal injury due to alcohol/drugs 12 (1.1) 2 (0.04) < 0.001 NA
Slow fetal growth 11 (1.0) 24 (0.5) 0.086 < 0.10
Fast fetal growth 11 (1.0) 23 (0.5) 0.068 < 0.10
Fear of childbirth 9 (0.8) 34 (0.7) 0.863 < 0.10
Pre-eclampsia 7 (0.6) 47 (1.0) 0.201 < 0.10
Exhaustion 7 (0.6) 7 (0.2) 0.005 0.19
Hepatogestosis 6 (0.5) 23 (0.5) 0.913 NA
Premature rupture of membrane 5 (0.4) 34 (0.7) 0.319 NA
Any vein complication 3 (0.3) 5 (0.1) 0.200 NA
Oligohydramnios 2 (0.2) 16 (0.3) 0.554 NA
Hyperemesis gravidarum 2 (0.2) 2 (0.04) 0.179 NA
Urogenital infection 2 (0.2) 6 (0.1) 0.663 NA
Symphyseolysis 2 (0.2) 3 (0.06) 0.287 NA
Suspected fetal hypoxia 1 (0.1) 0 (0.0) 0.199 NA
ES effect size, NA not applicable
*Leading to a delivery after the person was diagnosed with schizophrenia. The chi-square (χ2 ) test and Fisher’s
exact test was used to compare the groups. Coefficient Phi (x2 test) was used as an effect size measure
a Recorded since 2004
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severe mental disorder demonstrated that significant improve-
ments are achievable in blood glucose levels, especially when
the intervention is led by a dietician (Teasdale et al. 2017).
Although many antipsychotics are known to increase the risk
of gestational diabetes, women with schizophrenia are not
recommended to discontinue their medication during preg-
nancy (McCauley-Elsom et al. 2010) since relapse rates are
high (Spielvogel and Lee 2010) and untreated psychosis is a
serious risk for the fetus (Einarson 2010; Jablensky et al.
2005). The most up-to-date recommendation is to avoid
polypharmacy, use the lowest effective dose, and provide
close monitoring (Seeman 2013). If there are risk factors for
gestational diabetes, olanzapine should be avoided unless the
patient’s history suggests that a switch to another medication
Table 4 The risk of pregnancy-
related complications, disorders,
and hospitalizations among
women with schizophrenia when
controls served as a reference
group
First pregnancies* Unadjusted model,
OR (95% CI)
Adjusted model,
OR (95% CI)
Pathologic oral glucose tolerance test 2.00 (1.43–2.82)a 1.75 (1.24–2.46)a
Initiation of insulin treatment 1.09 (0.55–2.12) 1.51 (0.78–2.92)
Anemia 2.23 (1.02–4.86)a 2.25 (0.99–5.10)
Premature contractions 1.68 (0.92–3.10) 2.42 (1.31–4.49)a
Hypertension 1.15 (0.61–2.15) 1.81 (1.01–3.27)a
Individuals with one or more hospitalizations 1.91 (1.58–2.30)a 2.12 (1.73–2.58)a
All pregnancies* Unadjusted model,
OR (95% CI)
Adjusted model,
OR (95% CI)
Pathologic oral glucose tolerance test 1.79 (1.40–2.28)a 1.66 (1.27–2.17)a
Initiation of insulin treatment 1.32 (0.84–2.08) 1.84 (1.15–2.93)a
Anemia during pregnancy 1.82 (1.08–3.09)a 1.66 (0.94–2.94)
Antenatal corticosteroid treatment 1.14 (0.57–2.28) 0.95 (0.47–1.90)
Premature contractions 1.10 (0.57–2.28) 1.28 (0.78–2.10)
Hypertension 1.02 (0.59–1.76) 1.53 (0.91–2.56)
Fast fetal growth 1.92 (0.93–3.96) 1.62 (1.03–2.52)a
Slow fetal growth 1.84 (0.90–3.78) 1.53 (0.91–2.56)
Individuals with one or more hospitalizations 1.91 (1.65–2.22)a 1.97 (1.66–2.33)a
OR odds ratio, CI confidence interval
*Leading to a delivery after the person was diagnosed with schizophrenia. Results of logistic regression and
generalized estimating equation (GEE) models are provided. Maternal age at birth, marital status (dichotomous:
single vs. married or cohabitation), smoking status in the beginning of the pregnancy (yes vs. no), and parity were
used as covariates
a Statistically significant finding
Table 3 Prenatal carea among
women with schizophrenia (SZH)
and their controls
First pregnancies* SZH (n = 753) Controls (n = 2434) p value ES
Number of visits to municipal maternity
clinic; mean + SD
17.4 + 6.9 16.8 + 5.5 0.005 0.11
Number of outpatient visits to maternity
hospital; mean + SD
4.2 + 3.1 2.9 + 2.8 < 0.001 0.45
Persons with one or more hospitalizations; n (%) 235 (31.2) 464 (19.1) < 0.001 0.13*
All pregnancies* SZH (n = 1162) Controls (n = 4683) p value
Number of visits in municipal maternity
clinic; mean + SD
17.3 + 6.8 16.5 + 5.5 < 0.001 0.12
Number of outpatient visits to maternity
hospital; mean + SD
4.1 + 3.2 2.9 + 2.8 < 0.001 0.42
Persons with one or more hospitalizations; n (%) 332 (28.6) 809 (17.3) < 0.001 0.11*
SD standard deviation, ES effect size
*Leading to a delivery after the person was diagnosed with schizophrenia. The independent samples t test (visits)
and chi-square test (χ2 ) were used to compare the groups. Coefficient Phi (x2 test)* and Cohen’s d (independent
samples t test) were used as effect size measures
a Recorded since 1987
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significantly enhances her risk of recurrence (Barnes and
Schizophrenia Consensus Group of British Association for
Psychopharmacology 2011). In the case of clozapine, con-
cerns about the potential for relapse usually outweigh con-
cerns about its dysglycemic effect (Barnes et al. 2011).
In contrast to previous studies (Ellman et al. 2007; Judd et al.
2014; Nguyen et al. 2013; Vigod et al. 2014), we found no
group difference in pre-eclampsia/eclampsia. Regarding first
pregnancies, however, the risk of gestational hypertension
was almost 2-fold higher in women with schizophrenia.
Gestational hypertension is related to nulliparity, as well as to
overweight status and hyperglycemia (Shen et al. 2017) which
probably explains our finding. The risk of premature contrac-
tions wasmore than 2-fold higher in schizophrenic womenwith
their first pregnancies. Psychosocial factors like neuroticism
(Handelzalts et al. 2016), low education level, poor relation-
ships with others, as well as impaired coping skills
(Facchinetti et al. 2007) have all been associatedwith premature
contractions, which might, at least partly, explain this finding.
Regarding all pregnancies, the diagnosis of gestational exhaus-
tion was substantially more frequent among women with
schizophrenia than among non-affected women. These findings
highlight that psychosocial interventions to increase psycholog-
ical well-being and environmental mastery should be actively
offered to pregnant women with schizophrenia.
Schizophrenia and substance use disorders frequently co-
occur (Kessler et al. 2005). In this study, maternal care for
(suspected) harm to the fetus from alcohol and/or drugs was
fortunately rare, but substantially more common among wom-
en with schizophrenia than among non-affected women. Our
finding underlines that the monitoring of pregnant women
with schizophrenia should include substance use screening.
When necessary, treatment of concomitant substance misuse,
and schizophrenia should be integrated. The recommended
psychosocial treatments include motivational interviewing,
psychoeducation, and cognitive behavioral therapy (The
Finnish Medical Society Duodecim and the Finnish
Psychiatric Association 2015).
In line with earlier findings (Ellman et al. 2007; Vigod et al.
2014), we found that the number of visits to maternity clinics and
outpatient clinics of maternity hospitals, as well as the proportion
of womenwith one or more hospitalizations related to pregnancy
complications or disorders were significantly higher among
women with schizophrenia than among non-affected women.
In this perspective, pregnancies of women with schizophrenia
could be seen as challenging. These women have both psycho-
social and somatic problems and, because of this, intense collab-
oration between mental health providers, social workers, gyne-
cologists, and obstetrics is needed. Psychiatristsmust be prepared
to adjust antipsychotic doses frequently, as per clinical status
(Seeman 2013). Psychoeducation can reduce the risks of preg-
nancy complications for women with schizophrenia and short-
term focused psychotherapy can be useful for some pregnant
women with schizophrenia (Solari et al. 2009). If support net-
works around a mother-to-be with schizophrenia are lacking,
social services can provide supportive interventions. The
Finnish child welfare law was renewed in 2010; an anticipatory
child welfare notification can be made already during pregnancy
if there is a reason to assume that the newborn is going to need
actions of child welfare. The pregnancy-related complications
and disorders should be screened and treated as well as possible,
and it is suggested that mothers-to-be with schizophrenia should
be educated regarding signs of labor and familiarized in advance
with the setting in which the birth will take place (Seeman 2013).
Further research on maternal and fetal outcomes of childbirth is
also important.
Strengths and limitations
The strengths of this study include our ability to investigate the
Finnish national population of women with schizophrenia or
schizoaffective disorder, the relatively long follow-up time, and
the good-quality Finnish health registers (Aro et al. 1990; Gissler
et al. 1995). Also, the diagnoses of psychotic disorders have been
shown to be reliable (Isohanni et al. 1997; Pihlajamaa et al.
2008). However, some limitations need to be considered: first,
we used an age- and place-of-birth matched control group for
comparison, but confounding factors such as socioeconomic sta-
tus were not taken into account. This might have affected out-
comes such as nutrition and body weight. In Finland, most pa-
tients with schizophrenia are on disability pension (Perälä et al.
2008). However, the municipal healthcare services are funded by
tax revenues and are available to all citizens. Second, we were
limited to variables that were recorded in the national registers
described earlier. Unfortunately, we had no information about
women’s non-psychotic psychopathology, medications pre-
scribed to the women, utilization of mental health services, or
the nature or amount of their substance use.Women with schizo-
phrenia showed higher prevalence of psychosocial and somatic
risk factors related to pregnancy, as well as higher prevalence of
pregnancy-related complications and disorders as compared with
their non-affected counterparts, but it might also be that theywere
offered more intense prenatal care because of the psychiatric
disorder per se. On the other hand, we can verify that despite
their serious mental health disorder, women with schizophrenia
are able to use these services. Third, theremay also be differences
between individual clinicians and local customs within hospitals
in the diagnosis and reportage of ICD-10 diagnoses related to
childbirth. Fourth, we assumed that the onset of schizophrenia
was the day the disorder was diagnosed in specialized health care
and we had no information about psychotic symptoms before
this date. Neither had we information about women’s psychotic
symptoms during pregnancy. Fourth, the Medical Birth Register
was introduced in 1987, which means that our data did not com-
prise pregnancies before this. Fifth, considering the high number
of outcomes, some of the observed associations may have
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occurred by chance. Also, in bivariate analyses, effect sizes
showed only weak or moderate associations. Finally, the gener-
alizability of findings to other countries and settings need to be
examined. In particular, findings related to service use may vary
depending on models of provision and funding of services.
Conclusions
Women with schizophrenia show higher prevalence of psy-
chosocial and somatic risk factors related to pregnancy, as
well as conditions related to and aggravated by the pregnancy
than their non-affected counterparts. Targeted health educa-
tion and lifestyle interventions, as well as close collaboration
between mental health professionals, social workers, gynecol-
ogists, and obstetricians are needed.
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